Lindsey Kirchoff
Acute Care · Framingham, MANPI 1477914695
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,271 of the $2,071 with a category attached, or 61.4%. Medtronic accounts for 87.8% of it on its own, with 8 other manufacturers making up the rest.
Across 27 payments — averaging $76.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Novartis$63
- Boston Scientific$52
- Esperion Therapeutics, Inc.$30
- E.r. Squibb & Sons, L.L.C.$25
- Bayer$24
- plus $59 from 3 others
What the payments were for
- Travel & lodging$1,27161%
- Food & beverage$80039%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 17 | $1,818 |
| Novartis | 3 | $63 |
| Boston Scientific | 1 | $52 |
| Esperion Therapeutics, Inc. | 1 | $30 |
| E.r. Squibb & Sons, L.L.C. | 1 | $25 |
| Bayer | 1 | $24 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Abbott | 1 | $18 |
| Novo Nordisk | 1 | $18 |
How this compares
$2,071 in reported general payments places this provider in the 85th percentile of 307 acute care providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 75 | $114,582 |
| EntrestoSacubitril/Valsartan | 22 | $20,277 |
| Repatha SureclickEvolocumab | 14 | $19,280 |
| FarxigaDapagliflozin Propanediol | 14 | $12,291 |
| Metoprolol Succinate | 118 | $2,956 |
| Losartan Potassium | 41 | $613 |
| Atorvastatin Calcium | 42 | $527 |
| SotalolSotalol Hcl | 20 | $465 |
| ClopidogrelClopidogrel Bisulfate | 15 | $407 |
| Potassium Chloride | 15 | $352 |
| Torsemide | 14 | $343 |
| Warfarin Sodium | 16 | $320 |
| Lisinopril | 36 | $297 |
| Amlodipine Besylate | 32 | $241 |
| Metoprolol Tartrate | 19 | $211 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $63 | $20,27722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 307 acute care providers in Massachusetts.
Other acute care in Framingham
- Catherine CollierFramingham$9K
- Samantha NewmanFramingham$2K
- Bridgid JosephBoston$110K
- Pamela CalareseBoston$106K
- Kimberly GuiboneBoston$86K
- Audrey RoseWoburn$58K
- Danielle BeaulieuWest Springfield$21K
- Dawn NaylorBoston$13K
- Rebecca RathburnBoston$13K
- Morgan BowdenBoston$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.